Education
About Us
Working with TipRanks
Follow Us
Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Total Valuation
Australian Clinical Labs Ltd has a market cap or net worth of AU$495.35M. The enterprise value is AU$809.50M.
Market CapAU$495.35M
Enterprise ValueAU$809.50M
Share Statistics
Australian Clinical Labs Ltd has 195,791,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding195,791,380
Owned by Insiders<0.01%
Owned by Institutions―
Financial Efficiency
Australian Clinical Labs Ltd’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 39.51%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)39.51%
Return on Capital Employed (ROCE)0.76
Revenue Per Employee151.28K
Profits Per Employee6.62K
Employee Count4,900
Asset Turnover1.29
Inventory Turnover30.11
Valuation Ratios
The current PE Ratio of Australian Clinical Labs Ltd is 14.8. Australian Clinical Labs Ltd’s PEG ratio is 0.39.
PE Ratio14.8
PS Ratio0.71
PB Ratio3.09
Price to Fair Value3.09
Price to FCF3.03
Price to Operating Cash Flow2.42
PEG Ratio0.39
Income Statement
In the last 12 months, Australian Clinical Labs Ltd had revenue of 741.27M and earned 32.43M in profits. Earnings per share was 0.17.
Revenue741.27M
Gross Profit270.86M
Operating Income270.86M
Pretax Income48.18M
Net Income32.43M
EBITDA81.36M
Earnings Per Share (EPS)0.17
Cash Flow
In the last 12 months, operating cash flow was 182.80M and capital expenditures -8.41M, giving a free cash flow of 174.39M billion.
Operating Cash Flow182.80M
Free Cash Flow174.39M
Free Cash Flow per Share0.89
Dividends & Yields
Australian Clinical Labs Ltd pays an annual dividend of AU$0.09, resulting in a dividend yield of 4.94%
Dividend Per ShareAU$0.09
Dividend Yield4.94%
Payout Ratio71.43%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-27.46%
50-Day Moving Average2.55
200-Day Moving Average2.87
Relative Strength Index (RSI)50.79
Average Volume (3m)874.98K
Important Dates
Australian Clinical Labs Ltd upcoming earnings date is Feb 24, 2026, TBA (Confirmed).
Last Earnings DateAug 25, 2025
Next Earnings DateFeb 24, 2026
Ex-Dividend DateSep 01, 2025
Financial Position
Australian Clinical Labs Ltd as a current ratio of 0.55, with Debt / Equity ratio of 169.46%
Current Ratio0.55
Quick Ratio0.48
Debt to Market Cap0.08
Net Debt to EBITDA3.31
Interest Coverage Ratio14.75
Taxes
In the past 12 months, Australian Clinical Labs Ltd has paid 15.36M in taxes.
Income Tax15.36M
Effective Tax Rate0.32
Enterprise Valuation
Australian Clinical Labs Ltd EV to EBITDA ratio is 9.80, with an EV/FCF ratio of 4.57.
EV to Sales1.08
EV to EBITDA9.80
EV to Free Cash Flow4.57
EV to Operating Cash Flow4.36
Balance Sheet
Australian Clinical Labs Ltd has AU$22.12M in cash and marketable securities with AU$290.38M in debt, giving a net cash position of -AU$268.26M billion.
Cash & Marketable SecuritiesAU$22.12M
Total DebtAU$290.38M
Net Cash-AU$268.26M
Net Cash Per Share-AU$1.37
Tangible Book Value Per ShareAU$0.04
Margins
Gross margin is 36.54%, with operating margin of 36.54%, and net profit margin of 4.37%.
Gross Margin36.54%
Operating Margin36.54%
Pretax Margin6.50%
Net Profit Margin4.37%
EBITDA Margin10.98%
EBIT Margin9.17%
Analyst Forecast
The average price target for Australian Clinical Labs Ltd is AU$3.31, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$3.31
Price Target Upside31.87% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast6.73%
EPS Growth Forecast37.16%